Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer’s disease in a diverse cohort: MESA
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
Little is known about how Alzheimer’s disease (AD) plasma biomarkers relate to cerebral small vessel disease (cSVD) neuroimaging biomarkers.
METHODS
The study involved 251 Wake Forest Multi-Ethnic Study of Atherosclerosis (MESA) Exam 6 participants with plasma AD biomarkers, MRI, amyloid PET, and adjudicated cognitive status. Multivariable models examined cross-sectional relationships between plasma and neuroimaging biomarkers, considering comorbidities.
RESULTS
Lower Aβ42/Aβ40, and higher GFAP, NfL, and p-tau217 were associated with greater neurodegeneration. Lower plasma Aβ42/Aβ40 and higher p-tau217 and p-tau231 were associated with greater Aβ PET deposition. NfL was positively associated with WMH and WM Free Water. P-tau measures were positively associated with WM Free Water. Lower Aβ42/Aβ40 was associated with presence of microbleeds. GFAP was positively associated with WMH.
DISCUSSION
We observed expected associations of plasma biomarkers with cognitive status and imaging biomarkers. GFAP, NfL, p-tau181, p-tau217, and p-tau231 are associated with cSVD in addition to AD-related pathology.
